ABVC BioPharma (ABVC)
(Delayed Data from NSDQ)
$1.06 USD
-0.04 (-3.64%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.08 +0.02 (1.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for ABVC BioPharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 1 | 7 | 5 | 0 |
Receivables | 0 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 0 |
Total Current Assets | 2 | 3 | 10 | 6 | 1 |
Net Property & Equipment | 8 | 1 | 1 | 1 | 1 |
Investments & Advances | 4 | 4 | 1 | 1 | 3 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 1 | 2 | 1 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 0 | 0 | 0 |
Total Assets | 14 | 10 | 14 | 12 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 2 | 2 | 2 | 4 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 3 | 1 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 6 | 6 | 4 | 5 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 3 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 7 | 5 | 9 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 83 | 68 | 58 | 41 | 28 |
Retained Earnings | -65 | -54 | -38 | -26 | -16 |
Other Equity | 0 | -1 | -2 | -3 | -3 |
Treasury Stock | 9 | 9 | 9 | 9 | 9 |
Total Shareholder's Equity | 8 | 3 | 9 | 3 | 0 |
Total Liabilities & Shareholder's Equity | 14 | 10 | 14 | 12 | 7 |
Total Common Equity | 8 | 3 | 9 | 3 | 0 |
Shares Outstanding | 7.90 | 3.20 | 2.80 | 2.40 | 1.90 |
Book Value Per Share | 1.03 | 1.01 | 3.17 | 1.11 | -0.06 |
Fiscal Year End for ABVC BioPharma, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 1 | 1 | 2 |
Receivables | NA | 0 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 0 |
Total Current Assets | NA | 2 | 2 | 2 | 3 |
Net Property & Equipment | NA | 8 | 8 | 1 | 1 |
Investments & Advances | NA | 4 | 4 | 4 | 4 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 1 | 1 | 1 |
Total Assets | NA | 14 | 17 | 9 | 11 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 1 | 1 | 1 | 1 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 1 | 1 |
Total Current Liabilities | NA | 6 | 5 | 6 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 2 | 3 | 3 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 6 | 8 | 10 | 9 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 83 | 81 | 68 | 68 |
Retained Earnings | NA | -65 | -62 | -59 | -57 |
Other Equity | NA | 0 | 0 | 0 | -1 |
Treasury Stock | NA | 9 | 9 | 9 | 9 |
Total Shareholder's Equity | NA | 8 | 9 | 0 | 2 |
Total Liabilities & Shareholder's Equity | NA | 14 | 17 | 9 | 11 |
Total Common Equity | 0 | 8 | 9 | 0 | 2 |
Shares Outstanding | 10.50 | 7.90 | 4.80 | 3.30 | 3.30 |
Book Value Per Share | 0.00 | 1.03 | 1.89 | -0.11 | 0.52 |